Response to benralizumab in patients with severe eosinophilic asthma.

BACKGROUND

Severe asthma represents a significant public health challenge, and monoclonal antibodies such as benralizumab represent an effective therapeutic option for achieving disease control.

OBJECTIVE

To evaluate the effectiveness of benralizumab in patients with severe eosinophilic asthma by assessing changes in fractional exhaled nitric oxide (FeNO), peripheral blood eosinophils, symptom control, forced expiratory volume in 1 second (FEV1), and exacerbation rates six months after treatment initiation.

MATERIALS AND

METHODS

A prospective observational study was conducted in 11 patients with severe uncontrolled eosinophilic asthma. Clinical outcomes (ACT), quality of life (mini-AQLQ), FEV1, exacerbations, and biomarkers of blood eosinophils and FeNO were assessed at baseline and six months.

RESULTS

After six months of benralizumab therapy, > 90% of patients showed significant improvement in quality of life (mini-AQLQ, p < 0.05), and 72.7% achieved better asthma control (ACT, p < 0.05). Exacerbations decreased by 66.9% (p < 0.05). Blood eosinophils decreased by 97.5% (p < 0.05), FeNO by 57% (p < 0.05), and FEV1 increased by 27.7% (p < 0.05).

CONCLUSIONS

Benralizumab demonstrated significant clinical and inflammatory benefits in this cohort, improving biomarkers, lung function, exacerbation rates, and patient-reported outcomes, supporting its effectiveness in real-world management of severe eosinophilic asthma.